TOKYO, June 9, 2020 /PRNewswire/ -- FUJIFILM Corporation (President: Kenji Sukeno) will make a major capital investment of approximately 100 billion yen (928 million USD) in the Denmark site of FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization (CDMO) for biologics and advanced therapies. The capital investment will double the Denmark site's current drug substance manufacturing capacity, and will expand its capabilities to include fill/finish, and enhance its current assembly, labeling and packaging services.
The investment in FUJIFILM Diosynth Biotechnologies (Denmark) will expand production lines for bulk drug substance with the addition of a further six mammalian cell bioreactors, bringing the total to 12 x 20,000-liter bioreactors by fall 2023, making the Denmark facility one of the few major large-scale manufacturing facilities in the bio-CDMO industry. The development will also include the addition of the Denmark site's first fill/finish production line (added by summer 2023), featuring a fully-automated, cutting-edge system capable of producing up to approximately 35 million units per annum to cater to large-scale production. In spring 2022, a new packaging line equipped with facilities to assemble multiple types of auto-injectors*1 as well as automatic labeling, will be added to meet a broad range of customer needs.
"Our culture of innovation and reputation of manufacturing excellence ensures our rapid growth to better serve the healthcare community," said Takatoshi Ishikawa, executive vice president, general manager of bio-CDMO division, FUJIFILM Corporation. "Since the acquisition of the Denmark site last year, the facility's strong manufacturing track-record, coupled with FUJIFILM Diosynth Biotechnologies' technologies enabling a stable supply of high-quality biopharmaceuticals, has led to new orders not only from existing clients, but also new clients, contributing to our rapid business expansion."
In August 2019, Fujifilm invested approximately 98 billion yen (890 million USD) to acquire Biogen's manufacturing subsidiary in Denmark, for its world-class cGMP capabilities and its experienced talent.
The advanced capabilities at the Denmark site has led to promising collaborations including the recent announcement of future manufacturing capacity reservation by the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed-up the response to the global pandemic.
"With the addition of world-class assets enabling us to scale production volumes to fit both small and large batches, the capital infusion allows us to deliver on our promise to support our partners from pre-clinical through to commercialization," said Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. "Moreover, we are able to support our partners in manufacturing lifesaving therapies to patients around the world."
Fujifilm aims to achieve 100 billion yen in sales in its bio-CDMO business*2 by fiscal year ending March 2022, and 200 billion yen by fiscal year ending March 2026, while maintaining its commitment to support the delivery of wide variety of therapies and advancing healthcare.
*1 An auto-injector is a medical device for drug self-administration, designed to deliver a dose of a particular drug.
*2 Bio-CDMO business offers services for biopharmaceuticals and small molecule pharmaceuticals.
FUJIFILM Corporation, Tokyo, Japan is one of the major operating companies of FUJIFILM Holdings Corporation. The company brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: holdings.fujifilm.com
FUJIFILM Diosynth Biotechnologies an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerød, Denmark. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, go to: www.fujifilmdiosynth.com
All product and company names herein may be trademarks of their registered owners.
SOURCE FUJIFILM Diosynth Biotechnologies